Akari Therapeutics wins European patent for thailanstatin-based ADC payloads

Akari Therapeutics

Akari Therapeutics

AKTX

0.00
  • Akari Therapeutics secured a European patent covering Thailanstatin analogs used as RNA splicing modulator payloads for antibody-drug conjugates.
  • European Patent No. 3684773B1 provides composition-of-matter protection for payload chemistry underpinning lead ADC AKTX-101, with claims designed to support use with multiple linker technologies.
  • Patent strengthens IP position across major European markets, extending coverage to UK, Germany, France.
  • AKTX-101, a TROP2-targeting ADC using Akari’s PH1 payload platform, remains in IND-enabling studies with Phase 1 first-in-human trial expected by mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.